This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
This page is a summary of: Incidence and Characteristics of Naloxone Administration in Medical Oncology Patients with Cancer Pain, Journal of Pharmaceutical Care in Pain & Symptom Control, August 2000, The Haworth Press,
DOI: 10.1300/j088v08n02_05.
You can read the full text:
The following have contributed to this page
Endocrine Metabolic & Immune Disorders - Drug Targets
Diabetic Nephropathy (DN) is known as one of the driving sources of End-Stage Renal Disease (ESRD). DN prevalence continues to increase in every corner of the world andthat has been a major concern...
Current Pharmaceutical Design
More prospective study towards cancer by designing suitable drug by adopting computer aided drug design with use of pharmacokinetic model. Emphasis has been given use of chitosan in preparation of ...
Infection and Drug Resistance
The landscape of rotavirus (RV) infection has changed substantially in recent years. Autoimmune triggering has been added to clinical spectrum of this pathology, which is now known to be much broad...
